RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Meixatech, Yes, the BDNF upregulation aspect of high impact Ampakines could be ideal for stroke/TBI. However the downside is a high impact's inherent tendency to stimulate excitotoxicity/calcium imbalance at the synapse, which would be undesirable. Hopefully, by combining a short term "burst" dosing approach, with an ultra-short acting compound (of the safest compound family), the approach might end up being successful. As Neuro has said, TBI/Stroke has been a pharma graveyard for years, but perhaps the high impact Ampakine approach could be the exception.

BTW, I really thought PARS had a decent chance with their cannabinoid approach, but luckily I bailed out of the stock a week or so before the bad news. That near death experience contributed to my decision to go back to following biotech as a hobby :o)